Heart drug combo under microscope: will it help or harm?
NCT ID NCT07431294
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tests whether it is safe to take nitroglycerin spray (used for chest pain) together with an experimental drug called nurandociguat (designed to help kidneys) in 36 adults with stable coronary artery disease. Both drugs widen blood vessels, so the main concern is a sudden drop in blood pressure. The study will monitor side effects and how the drugs interact in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nitroglycerin spray and nurandociguat
What this could lead to
If successful, this could show that combining nitroglycerin with nurandociguat is safe, potentially leading to better treatment options for people with both heart and kidney disease.
What could go wrong
This is a very early Phase 1 safety study with only 36 participants. It is not designed to prove effectiveness, and the combination may cause low blood pressure or other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STABLE CORONARY ARTERY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Comac Medical | Phase I Clinical Research Unit
Sofia, Sofia City Province, 1000, Bulgaria
-
Deutsches Herzzentrum der Charité (DHZC) - Klinik für Kardiologie, Angiologie und Intensivmedizin CVK
Berlin, 13353, Germany
-
SocraTec R&D Erfurt-Clinical Pharmacology Unit
Erfurt, Thuringia, 99084, Germany
-
UK Bonn Institut für Klinische Chemie und Klinische Pharmakologie, Phase I Einheit und Arzneimitteltherapiesicherheit
Bonn, North Rhine-Westphalia, 53127, Germany
-
Universitätsklinikum Heidelberg - Zentrum für Innere Medizin, Abteilung Klinische Pharmakologie und Pharmakoepidemologie
Heidelberg, Baden-Wurttemberg, 69120, Germany